Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 MH086828)
Received: 14 May 2023
Revised: 14 July 2023
Accepted: 8 August 2023
First Online: 14 September 2023
: The University of Maryland Baltimore has patents, on which I am listed as an inventor, covering the use of α5-selective NAMs to treat psychiatric disease.